Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib + dexamethasone induction followed by high-dose melphalan and autologous stem cell transplantation in de novo AL amyloidosis
2010-021445-42Phase 2Completed
- Sponsor
- HOVON
- Start
- Jan 2011
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in light-chain amyloidosis, sponsored by HOVON. Primary endpoint: Hematological complete response rate at 6 months after autologous stem cell transplantation. Started Jan 2011; status: completed.
02
Drugs
bortezomib
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2010-021445-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021445-42.